3 results
Approved WMORecruiting
Safety and efficacy objectives:The objective is to compare the safety and efficacy of masitinib at 6 of 7.5 mg/kg/day to imatinib at 400 or 600 mg, in patients with gastro-intestinal stromal tumour in first line medical treatment.
Approved WMOCompleted
The objective of this study is to demonstrate the safety and effectiveness of the Hydrus Aqueous Implant for lowering IOP in patients with primary open-angle glaucoma (POAG) who are undergoing concurrent cataract surgery.
Approved WMORecruiting
The objective is to compare the efficacy and safety of masitinib 12 mg/kg/day to sinutinib 50 mg/day